AZT: Prolonging Life But Not Stopping Death

Helquist, Michael
March 1987
Advocate;3/3/87, Issue 467, p23
Reports that the medical advisers of the U.S. Food and Drug Administration have recommended in 1987 the licensing of AZT for sale to a restricted group of patients with AIDS or severe ARC. Initial results of studies on AZT; Benefits from taking AZT; Researchers' concerns about side effects.


Related Articles

  • New Report on AZT. Helquist, Michael // Advocate;1/17/89, Issue 516, p30 

    Reports on a study indicating that azidothymidine (AZT) can reverse the deterioration in mental and cognitive capabilities often experienced by individuals with AIDS or AIDS-related complex. Support for anecdotal reports on the benefits of the antiviral drug; Details of the study.

  • Drug Combo Update. Helquist, Michael // Advocate;10/29/85, Issue 432, p23 

    Reports on the effectiveness of using two drugs, isoprinosine and ribavirin to treat AIDS and AIDS-related complex. Existing practice of administering the drugs to patients; Mechanism of treatment; Implications for AIDS treatment.

  • Low Toxicity Reported With AIDS Drug CS-85. Helquist, Michael // Advocate;1/6/87, Issue 463, p23 

    Reports that the drug AZT continues to be a focal point for the hopes of people infected with HIV and those diagnosed with AIDS. Emphasis made on the lower mortality rate associated with the drug; Inhibition of the growth of the HIV.

  • The AZT fire storm. Gallagher, John // Advocate;5/18/93, Issue 629, p29 

    Reports on the controversy surrounding the effectiveness of AZT in the treatment of AIDS. Article published in a medical journal claiming that the antiviral drug may not slow the onset of AIDS in HIV-infected persons; Reaction of AIDS activists.

  • AZT is shit. Kramer, Larry // Advocate;5/18/93, Issue 629, p80 

    Focuses on the ineffectiveness of AZT in the treatment of AIDS. Criticism on concerned agencies for failure to discover and produce AIDS drugs; Government budget for AIDS research.

  • Timing of AZT. M.O.R. // Cortlandt Forum;03/25/97, Vol. 10 Issue 3, p139 

    Warns against the use of zidovudine monotherapy in newly diagnosed HIV patients. Drugs which could be combined with zidovudine to increase anti-HIV activity; Factors on which decisions about when to initiate treatment are usually based.

  • AZT Summary. Helquist, Michael // Advocate;4/28/87, Issue 471, p23 

    Discusses issues related to AZT, the first AIDS drug licensed by the U.S. Food and Drug Administration. Marketing of the drug under the brand name Retrovir; Limited supplies of the drug; Recommended dosage.

  • No Time to Relax. Helquist, Michael // Advocate;4/28/87, Issue 471, p23 

    Focuses on licenses for the AIDS drug AZT or Retrovir in the U.S., Great Britain and France. Hope given to people infected with HIV; Criticism on the limited availability of the drug; Flaws in the American health care system and the government's response to AIDS research.

  • Optimism about New Drug. Helquist, Michael // Advocate;3/4/86, Issue 441, p23 

    Highlights the results of a small-scale clinical trial of azidothymidine. Efficacy of the drug in preventing the AIDS virus from reproducing in the body; Need for more extensive studies.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics